by: haya m. al-malaq clinical pharmacy department ksu

52
By: Haya M. Al-Malaq Clinical pharmacy department KSU

Upload: isis-bardon

Post on 14-Dec-2015

215 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: By: Haya M. Al-Malaq Clinical pharmacy department KSU

By: Haya M. Al-Malaq

Clinical pharmacy department

KSU

Page 2: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Introduction

TB is the leading global infectious killer with 2.9 million deaths annualy.

Page 3: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Characteristics of the organism

M. tuberclusis is an acid fast bacillus b/c of its resistance to decolonization by acid alcohol after staining with basic function.

It thrives in environments with high O2 tension. (e.g. epics of the lung)

Page 4: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Risk factors

Immunosuppressant.

Poor nutrition.

DM.

Crowded living conditions.

Various chronic diseases.

Page 5: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Pathophysiology

The inflammation produced with TB infection is granulomatous, with epithelioid macrophages and Langhans giant cells along with lymphocytes, plasma cells, maybe a few PMN's, fibroblasts with collagen, and characteristic caseous necrosis in the center.

The inflammatory response is mediated by a type IV hypersensitivity reaction.

Page 6: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Diagnosis

Subjective findings

Objective findings

Potential misdiagnoses

Page 7: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Subjective Findings

Productive cough

Fatigue

Night sweats

Fever

Pleuritic pain

General malasie

Dyspnea

Page 8: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Objective findings

Chest radiograph( lower RTI, nodular infiltrates)

Positive sputum smear for AFB

Positive PPD skin test (14mm)

Hematologic manifestation (leukocytosis,Anemia)

Page 9: By: Haya M. Al-Malaq Clinical pharmacy department KSU
Page 10: By: Haya M. Al-Malaq Clinical pharmacy department KSU

PPD skin test

Chapter 61 page 4

Page 11: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin testMantoux method

Diagnostic tool used to detect infection with M.tuberculosis but not active TB.PPD refers to Purified Protein Derivative of M.tuberculosis, which is prepared from a culture of tubercle bacilli.The solution available:1 TU per0.1ml5 TU Per 0.1ml250 TU Per 0.1ml

Page 12: By: Haya M. Al-Malaq Clinical pharmacy department KSU
Page 13: By: Haya M. Al-Malaq Clinical pharmacy department KSU

PPD skin test method

1. Injecting 0.1ml of 5TU PPD intradermaly into volar or dorsal surface of the forearm.

2. If the patient previously infected with M.tuberculosis,sensitized T cells are recruited to the skin site

T cells cytokines induration

(raised area)

Page 14: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

Induration is local vasodilatation, edema,fibrin deposition, and recruitment of other inflammatory cells to the area.

The reaction to tuberculin begins 5-6hr.

Max induration observed 48-72hr.

The diameter of the induration should be measured in millimeters.

Page 15: By: Haya M. Al-Malaq Clinical pharmacy department KSU
Page 16: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

Induration≥5mm consider to be a positive reaction:

1. Recent history of close contact

2. Fibrotic changes on chest radiograph consistent with old TB

3. Organ transplant patients

4. Immunosuppressed patients

5. HIV positive persons

Page 17: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

Induration size of 10mm is used as the cut point for +vety in clinical condition that inc risk of TB:

1. DM

2. Silicosis

3. CRF

4. Leukemia

5. Lymphoma

6. Gastrectomy

7. Wt loss of >10% of ideal body wt.

Page 18: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

Induration ≥10mm is considered to be +ve: 1. Countries with high prevalence of TB

2. Drugs users

3. Employees of high-risk congregate settings

4. Mycobacteriology laboratory personnel

5. Children <4 years of age

Page 19: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

False-positive tuberculin skin test:1. Infection secondary to other mycobacterial

species

2. BCG vaccine

3. Impurities in the solutions

False-negative tuberculin skin test:1. Bacterial, viral,fungal

2. Vaccination

3. CRF

4. Disease of lymphoid organ

5. Age

6. Drugs

Page 20: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

False-negative tuberculin skin test occur 25%

Anergy decresed ability to respond to antigens due to sever debility, old age,immaturity in newborns,live vaccinations

Page 21: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Tuberculin PPD skin test

Positive PPD skin test DOSE NOT confirm diagnosis of active TB.

Other test to confirm TB:1. Sputum culture(AFB)

2. Gastric aspiration

3. Spinal fluid

4. Urineanalysis

5. Tissue biopsy

Page 22: By: Haya M. Al-Malaq Clinical pharmacy department KSU

AFB

Limmitation of AFB:1. Negative AFB dose not rule out active TB

2. AFB dose not has the ability to differentiate between mycobacterial species & viable-nonviable bacteria.

Page 23: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case 1

Chapter 61 page 3

Page 24: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case

M.W 36 yo f

CC: 2m history of cough recently became productive, she also is experiencing fatige, night sweats, wt loss 10Ib.

Other medical problem DM (10u NPH daily, poor nutritional status 2ry to frequent dieting.

She works as a volunteer in a nursing home several days a wk.

Page 25: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case

Recently it has been discovered that 2 pt that she has been caring for had active TB.

PE: N, CXR reviled bibasilar infiltrates.

PPD, AFB, CLT of sputum was ordered.

Initial labs were WNL.

PPD was 14mm ein 48hrs, sputum smear was +ve for AFB, MTB culture was ordered to confirm the diagnosis.

Page 26: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Questions

What S&O findings dose M.W have that r consistent with TB?

What is PPD skin test? How should results be interperted in M.W?

b/c M.W PPD skin test is +ve, does this confirm the diagnosis of active TB?

Page 27: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Questions

Should M.W be tested for HIV?

Would a –ve PPD skin test eliminate the possibility of infection in M.W?

Page 28: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case 6

Chapter 61 page 6

Page 29: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Booster Phenomenon

S.N 50 yo hospital employee receiving his initial PPD skin test (PPD-mantoux), & had a 7 mm induration.

b/c of his age & previous hospital employment, it was decided to retest him 1 wk later to rule out “booster” effect.

the results of the repeated test was 12 mm, he denied any exposure to a person with TB.

Page 30: By: Haya M. Al-Malaq Clinical pharmacy department KSU

What is the significance of this reaction?

Should S.N be placed on INH therapy for latent TB infection?

Page 31: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Definition

Some people experience increase in size of a TB skin test not caused by TB infection.

Page 32: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Possible Causes

TB skin test it self if preformed every 1-2 yrs.

Infection with other mycobacteria.

Remote TB.

Prior BCG vaccination.

The incidence of the rx increase with age & may appear 1 wk after the previous test.

Page 33: By: Haya M. Al-Malaq Clinical pharmacy department KSU

How to know

2 step skin test is for new employee only.

If the repeated test is +ve (>10 mm)--- booster phenomena.

If change to +ve but <10 mm (6 mm inc) after 1 yr---recent converter.

Page 34: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case 7

Chapter 61 page 6-7

Page 35: By: Haya M. Al-Malaq Clinical pharmacy department KSU

BCG Vaccine

C.T is a 25 yo F refugee from Combodia, was given a routine PE upon entering this country.

As a part of this examination, she received a tuberculin skin test with 5TU PPD.

The test results were +ve with 12mm induration.

She denies receiving TB tx but remembered receiving BCG vaccine several yrs agp

Page 36: By: Haya M. Al-Malaq Clinical pharmacy department KSU

What is BCG vaccine?

Does this +ve skin test indicate infection with MTB?

Page 37: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case 29

Chapter 61 page 22

Page 38: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case

E.F, 25 yo f, treated with:

INH (15 mg/kg)

Rifampin 600 mg twice a wk.

For uncomplicated TB, thinks she is pregnant

Page 39: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Risk / Teratogenicity

Should therapeutic abortion be considered?

What are the risks of TB & its treatment on the mother & fetus?

Are these drugs teratogenic?

Page 40: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Risk / Teratogenicity

Untreated TB is greater risk than treatment.

INH, Rif, Eth are teratogenic in animals not in humans.

They are safe to use in normal dose in pregnancy.

Page 41: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Risk / Teratogenicity

Pyrazinamide has been used safely but its teratogenic potential has not been studied adequately for FDA approval, it is only reserved for resistant cases.

All pregnant women receiving INH should receive pyridoxine 25 mg/d b/c of the possibility of CNS toxicity.

Page 42: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Risk / Teratogenicity

There is some risk of limb malformation & hypoprothrombinemia but not stat sig.

Streptomycin should not be used (except as a last alternative) b/c of risk of ototoxicity.

Therapeutic abortion is not recommended.

INH, rif, eth safely used for 9 m.

Page 43: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Lactation

E.F may breast-feed while taking her medn.

Page 44: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Case 30

Chapter 61 page 22-23

Page 45: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Pediatrics

A.M is a 3 yo African American boy, is suspected of having TB.

His father has been receiving tx for TB for the last 2 m.

He has productive cough, fever, & general malaise.

His sputum is +ve for AFB, & +ve PPD skin test (10 mm).

Page 46: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Pediatrics

What is the incidence of TB in children?

How should A.M. be treated?

Page 47: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Pediatrics

Incidence dec 3/100000 in 1993 to 1.5/100000 in 2001.

b/c of risk of disseminated TB pt should be tx asap (directly after diagnosis).

The same regimen as for adults except for Eth (difficulty in assessing visual acuity).

Page 48: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Pediatrics

3 drug combination is recommended b/c of lo bacillary population & difficulty for an infant to take 4 drug.

Regamin is INH (10-15mg/kg/d)+ Rif (10-20mg/kg/d)+ Pyrz (15-30mg/kg/d) for 8 wks then INH+Rif daily or 2-3t/wk for 4m (no resistance).

Page 49: By: Haya M. Al-Malaq Clinical pharmacy department KSU

Pediatrics

If resistance is suspected add Eth (15-20mg/kg/d) until susceptibility is confirmed.

Examine routinely for hepatitis, occurs within 3 months of therapy and more associated with hi dose & combination therapy.

Page 50: By: Haya M. Al-Malaq Clinical pharmacy department KSU

High-Priority Candidates for Treatment of Latent Tuberculosis Infection

Treatment Should be recommended for the following persons with a positive tuberculin skin test, regardless of age:.

Persons with known or suspected HIV infection.

Close contacts with infectious TB.

Recent tuberculin skin test converters.

DM, corticosteroids and immunosuppressive therapy, ESRD injection drug users, rapid weight loss.

Page 51: By: Haya M. Al-Malaq Clinical pharmacy department KSU

High-Priority Candidates for Treatment of Latent Tuberculosis Infection

Treatment Should be recommended for the following persons with a positive tuberculin skin test who are < 35 years of age and do not have additional risk factors:.

Foreign-born persons from high-prevalence countries.

Medically underserved low-income populations.

Resident of facilities for long term care.

Page 52: By: Haya M. Al-Malaq Clinical pharmacy department KSU